alexa Single Chain Antibodies Fragment (scFv) Coupled By Trimerization Domains, An Alternative To Monoclonal Antibody Therapy | 68364
ISSN: 2169-0138

Drug Designing: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th Annual Congress on Drug Discovery & Designing
July 03-04, 2017 Bangkok, Thailand

Lionel Zapata
University of Concepcion, Chile
Posters & Accepted Abstracts: Drug Des
DOI: 10.4172/2169-0138-C1-014
Abstract
Many different monoclonal antibodies (Mabs) are already available for cancer, chronic infections and autoimmune diseases therapy. Over the last few years biopharmaceutical companies have experienced a huge improvement in the Mabs manufacturing process, however the antibody based therapies still remain too expensive. Because of the molecular nature of mAbs, the recombinant expression in mammalian cells cannot be replaced by less expensive alternatives such as bacteria or yeast culture. Here, we propose a molecular alternative for therapeutic mAbs, based on fragments of single chain antibodies (scFv) coupled through trimerization domain of tetranectin. Trimeric scFvs share with Mabs the domains involve in target recognition and have a similar molecular weight. These trimeric scFv can be successful expressed in cheaper platforms as yeasts or bacteria culture. To obtain scFvs coupled through trimerization domains the yeast expression vector pPSHG20-tetra was constructed by restriction cloning. This vector codes for the expression of an anti-VEGF scFv coupled by the tetranectin trimerization domain following by a poly histidine tag was added to N-terminal, to facilitate identification and subsequent purification. MP-36 yeast strain was transformed with the plasmid-tetra pPSHG20 by electroporation and transformed cells were isolated by auxotrophy selection and the insertion was checked by Southern blotting. Trimeric scFv expression was performed with 0.7% methanol during 4 days. Then trimeric scFvs were purified using affinity purification by IMAC. The protein expression yield and the ability to trimerize were analyzed by SDS-PAGE, Western blotting and densitometry, in reducing and non-reducing conditions. Finally, the bioactivity of trimeric scFv was confirmed by in vitro and in vivo models. As a result, we demonstrated that the expression of high yields of trimeric scFv fragments in yeast is possible. The estimated molecular weight of trimeric scFv was similar to the IgG antibody isotype. Furthermore, trimers of scFv fragments were obtained with high purity (95%) and remained their trimeric structure. The trimeric ati-VEGF scFv antibodies inhibit the biologic activity of human VEGF in in vitro and in vivo assay. This results suggests that functional scFv coupled trough trimerization domains production is possible. The trimeric scFv could be al reliable alternative to the Mabs based therapy with similar bioactivity but with a lower production cost.
Biography

Lionel Zapata is currently a PhD student of the University of Concepcion, Chile. He has obtained his Master's degree in Physiology in 2015. He is a member of biotechnological company dedicated to the development of biotechnological solutions for the pharmaceutical area.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]icsonline.com

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version